Cymabay Therapeutics Total Liabilities

Cymabay Therapeutics (CBAY) currently reports a total liabilities of $140M as of December 2023. That compares with $110M in the prior-year period — up 34.8% year over year. Use the charts on this page to explore Cymabay Therapeutics's total liabilities history and peer comparisons.

Cymabay Therapeutics's total liabilities increased from $110M to $140M — a 34.8% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cymabay Therapeutics reported $140M in total liabilities as of December 2023. That compares with $110M in the prior-year period — up 34.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $140M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cymabay Therapeutics, and consider following CBAY for alerts when major investors trade the stock.

Cymabay Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $140M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CBAY with unrelated industries.